Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.63 |
| ▸ | TBXAS1 | P24557 | 10/20 | 0.62 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | JUN | P05412 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | APAF1 | O14727 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7957742 | 1.00 | AKR1C3 (0.63) | AKR1C3TBXAS1CYP11B2CYP19A1MAPT | |
| SCHEMBL7127950 | 0.87 | MAPT (0.55) | AKR1C3TBXAS1CYP11B2CYP19A1MAPT | |
| SCHEMBL1583517 | 0.87 | MAPT (0.55) | AKR1C3TBXAS1CYP11B2CYP19A1MAPT | |
| SCHEMBL25420502 | 0.84 | MAPT (0.52) | AKR1C3TBXAS1CYP11B2CYP19A1MAPT | |
| SCHEMBL20095536 | 0.84 | MAPT (0.52) | AKR1C3TBXAS1CYP11B2CYP19A1MAPT | |
| SCHEMBL6855117 | 0.83 | MAPT (0.55) | TBXAS1CYP11B2CYP19A1MAPTLMNA | |
| SCHEMBL6856019 | 0.83 | MAPT (0.55) | TBXAS1CYP11B2CYP19A1MAPTLMNA | |
| SCHEMBL11864148 | 0.81 | CYP11B2 (0.58) | TBXAS1CYP11B2CYP19A1MAPTLMNA | |
| SCHEMBL8039279 | 0.80 | MAPT (0.59) | CYP11B2CYP19A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL11063685 | 0.80 | TBXAS1 (0.74) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103834184-B | A kind of high-modulus asphalt and preparation method thereof | 山西省交通科学研究院 | 2016-09-28 | — | — | CN | claimed |
| EP-3191590-B1 | SORBENT MATERIAL FOR SEPARATING BIO-MACROMOLECULES | QUANTUMDX GROUP LTD (GB) | 2024-02-21 | — | — | EP | disclosed |
| US-10792640-B2 | Sorbent material for separating bio-macromolecules | QUANTUMDX GROUP LIMITED (GB) | 2020-10-06 | — | — | US | disclosed |
| US-9938258-B2 | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170282154-A1 | SORBENT MATERIAL FOR SEPARATING BIO-MACROMOLECULES | QUANTUMDX GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| EP-3191590-A1 | SORBENT MATERIAL FOR SEPARATING BIO-MACROMOLECULES | Quantumdx Group Limited (GB) | 2017-07-19 | — | — | EP | disclosed |
| CN-103834184-B | A kind of high-modulus asphalt and preparation method thereof | 山西省交通科学研究院 | 2016-09-28 | — | — | CN | disclosed |
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | Karyopharm Therapeutics Inc. | 2016-08-04 | — | — | US | disclosed |
| WO-2016040697-A1 | SORBENT MATERIAL FOR SEPARATING BIO-MACROMOLECULES | QUANTUMDX GROUP LIMITED (GB) | 2016-03-17 | — | — | WO | disclosed |
| EP-2925750-A1 | SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics, Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014085607-A1 | SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2014-06-05 | — | — | WO | disclosed |
| US-6255490-B1 | TREATING DISORDERS ASSOCIATED WITH CHANGES IN CHOLINERGIC ACTIVITY; NON-OPIATE BASED ANALGESIC FOR MODERATE TO SEVERE PAIN EQUALLY OR EXCEEDING THE POTENCY OF OPIATE ANALGESICS, YET LACKING ADDICTIVE SIDE EFFECTS | UNIVERSITY OF VIRGINIA | 2001-07-03 | — | — | US | disclosed |
| US-6117889-A | 7-Azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents | UNIVERSITY OF VIRGINIA (US) | 2000-09-12 | — | — | US | disclosed |
| US-6060473-A | 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands | UCB S.A. - DTB (BE) | 2000-05-09 | — | — | US | disclosed |
| EP-0778835-A4 | 7-AZABICYCLO 2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS CHOLINERGIC RECEPTOR LIGANDS | UNIV VIRGINIA (US) | 1999-02-03 | — | — | EP | disclosed |
| US-5817679-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | UNIVERSITY OF VIRGINIA (US) | 1998-10-06 | — | — | US | disclosed |
| EP-0778835-A1 | 7-AZABICYCLO 2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS CHOLINERGIC RECEPTOR LIGANDS | UNIVERSITY OF VIRGINIA (US) | 1997-06-18 | — | — | EP | disclosed |
| EP-0691971-A1 | 7-AZABICYCLO- 2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS ANALGESICS AND ANTI-INFLAMMATORY AGENTS | UNIVERSITY OF VIRGINIA (US) | 1996-01-17 | — | — | EP | disclosed |
| WO-1994022868-A1 | 7-AZABICYCLO-[2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS ANALGESICS AND ANTI-INFLAMMATORY AGENTS | UNIVERSITY OF VIRGINIA (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | BCL6, MALT1, BCL3 | AKR1C3 623/4885TBXAS1 4021/4885CYP11B2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.